SK Biopharm "Awarded '100 Million Dollar Export Tower' as Korea's First Single New Drug"

SK Biopharm Cenobamate (US sales name Xcopri). [Photo by SK Biopharm]

[Asia Economy Reporter Lee Gwan-joo] SK Biopharm announced on the 6th that it received the '100 Million Dollar Export Tower' award at the '59th Trade Day' ceremony.

SK Biopharm's independently developed innovative epilepsy drug, Cenobamate, surpassed $100 million in exports to the United States and Europe from July 1 of last year to June 30 of this year. This is the first time a domestic pharmaceutical company has received the 100 Million Dollar Export Tower award for a single innovative drug developed in-house.

Cenobamate received marketing approval from the U.S. Food and Drug Administration (FDA) in 2019 and successfully established itself in the U.S. market under the product name XCOPRI®. SK Biopharm is accelerating its global expansion, leveraging the commercialization of Cenobamate in the U.S. Last year, it also entered the European market with its partner Angelini Pharma under the product name ONTOZRY®.

The company stated that this award is encouraging as it was achieved just two years after Cenobamate entered the U.S. and European markets.

Meanwhile, the Export Tower award ceremony is held annually on December 5, Trade Day, organized by the Korea International Trade Association. The association awards the 'Export Tower' to export companies that have contributed to Korea's international status and economic development over the past year.

This content was produced with the assistance of AI translation services.